T. Rowe Price Investment Management, Inc. Biogen Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,394,476 shares of BIIB stock, worth $202 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
1,394,476
Previous 2,660,290
47.58%
Holding current value
$202 Million
Previous $364 Million
51.89%
% of portfolio
0.11%
Previous 0.24%
Shares
9 transactions
Others Institutions Holding BIIB
# of Institutions
1,018Shares Held
131MCall Options Held
2.87MPut Options Held
2.57M-
Vanguard Group Inc Valley Forge, PA17.3MShares$2.5 Billion0.04% of portfolio
-
Primecap Management CO Pasadena, CA15.8MShares$2.29 Billion1.62% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.11 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.47MShares$1.08 Billion0.04% of portfolio
-
Wellington Management Group LLP Boston, MA4.8MShares$695 Million0.11% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $20.9B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...